- Home
- ENTX vs NSPR Comparison
ENTX vs NSPR Comparison
Compare ENTX & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- NSPR
- Stock Information
- Founded
- ENTX 2010
- NSPR 2005
- Country
- ENTX Israel
- NSPR Israel
- Employees
- ENTX N/A
- NSPR N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- NSPR Medical/Dental Instruments
- Sector
- ENTX Health Care
- NSPR Health Care
- Exchange
- ENTX Nasdaq
- NSPR Nasdaq
- Market Cap
- ENTX 69.6M
- NSPR 75.6M
- IPO Year
- ENTX 2018
- NSPR N/A
- Fundamental
- Price
- ENTX $1.70
- NSPR $2.69
- Analyst Decision
- ENTX Strong Buy
- NSPR Strong Buy
- Analyst Count
- ENTX 1
- NSPR 2
- Target Price
- ENTX $10.00
- NSPR $4.75
- AVG Volume (30 Days)
- ENTX 52.4K
- NSPR 67.4K
- Earning Date
- ENTX 03-28-2025
- NSPR 03-12-2025
- Dividend Yield
- ENTX N/A
- NSPR N/A
- EPS Growth
- ENTX N/A
- NSPR N/A
- EPS
- ENTX N/A
- NSPR N/A
- Revenue
- ENTX $181,000.00
- NSPR $7,009,000.00
- Revenue This Year
- ENTX N/A
- NSPR $50.18
- Revenue Next Year
- ENTX N/A
- NSPR $159.56
- P/E Ratio
- ENTX N/A
- NSPR N/A
- Revenue Growth
- ENTX N/A
- NSPR 12.96
- 52 Week Low
- ENTX $1.41
- NSPR $1.81
- 52 Week High
- ENTX $3.35
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- ENTX 33.66
- NSPR 39.79
- Support Level
- ENTX $1.85
- NSPR $2.57
- Resistance Level
- ENTX $2.02
- NSPR $2.78
- Average True Range (ATR)
- ENTX 0.10
- NSPR 0.20
- MACD
- ENTX -0.01
- NSPR -0.01
- Stochastic Oscillator
- ENTX 11.57
- NSPR 17.72
Stock Price Comparison Chart: ENTX vs NSPR
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.